著者

Yuhi SAITO Toshihiro MIHARA Kentaro MARUYAMA Jiro SAITO Masumi IKEDA Akihito TOMONAGA Takehisa KUMAGAI

出版者

BMFH出版会

雑誌

Bioscience of Microbiota, Food and Health (ISSN:21863342)

巻号頁・発行日

pp.16-031, (Released:2017-04-14)

被引用文献数

16

---

Lactic acid bacteria are gut flora that play key roles in intestinal homeostasis, which may affect a variety of physiological functions. Our preliminary double-blind, placebo-controlled, parallel-group trials have suggested that intake of heat-killed Lactobacillus casei subsp. casei 327 (designated lactobacillus K-1) is effective for improving skin conditions. The aim of this study was to confirm the effect of lactobacillus K-1 intake in a randomized, double-blind, placebo-controlled, parallel-group study in healthy female volunteers. Sixty-four subjects were allocated to either the placebo food group (group P, n=32) or active food group (group A, n=32), in which subjects consumed lactobacillus K-1 50 mg (approximately 1 × 1011 bacteria) daily for 8 weeks. After excluding subjects who declined to participate (n=1), violated restrictions (n=4), or were judged ineligible by the principal investigators (n=1), data obtained with 58 subjects (30 in group A and 28 in group P) were analyzed for efficacy by comparing differences from pretrial levels between the two groups. When the level of transepidermal water loss (TEWL) was measured at the arm, the level of TEWL at week 4 of the intake period was significantly lower in group A than group P (p=0.021), suggesting an improvement of skin barrier function. Analysis of skin condition questionnaire data revealed a significant reduction in skin flakiness on the face (week 4). No adverse events were associated with intake of the test foods. The safety of lactobacillus K-1 was also confirmed in an independent open-label trial in 11 healthy subjects who consumed excessive amounts of lactobacillus K-1 250 mg (approximately 5 × 1011 bacteria). Intake of lactobacillus K-1 may therefore be beneficial to skin condition improvement.

著者

Yuhi SAITO Mikio FUJII Toshiyuki WATANABE Kentaro MARUYAMA Yasuyuki KOWATARI Hiromaru OGATA Takehisa KUMAGAI

出版者

BMFH出版会

雑誌

Bioscience of Microbiota, Food and Health (ISSN:21863342)

巻号頁・発行日

vol.36, no.2, pp.55-63, 2017 (Released:2017-04-19)

参考文献数

24

被引用文献数

7

---

Lactobacillus paracasei K71 was shown to be effective in alleviating the severity of atopic dermatitis in a randomized controlled trial, and a preliminary open-label trial suggested that strain K71 intake enhanced secretory immunoglobulin A (sIgA) release in the saliva. This study investigated the effect of K71 on sIgA release in a randomized, double-blind, placebo-controlled, parallel-group trial. The trial included 62 Japanese subjects aged 20–64 years with relatively low rates of salivary sIgA release. Subjects (n=31 in each group) were randomly given a tablet containing 100 mg (approximately 2 × 1011 bacteria) of K71 or a placebo tablet daily for 12 weeks. After eliminating data for eight subjects (four in each group) who met the exclusion criteria for efficacy analysis, data for 54 subjects were analyzed. The change in the rate of salivary sIgA release 8 weeks after initiation of the study compared with baseline was significantly higher in the K71 tablet group (105.5 ± 119.0 µg/min) than in the placebo group (52.7 ± 62.6 µg/min; p=0.047). There were no adverse events associated with intake of tablets containing K71. The safety of intake of L. paracasei K71 was also confirmed in an independent open-label trial with 20 healthy subjects who consumed excessive amounts of K71-containing food. L. paracasei K71 intake may therefore have some benefits in promoting mucosal immune function.